Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of crohn’s disease
3.2.1.2 Advancement in diagnostic techniques
3.2.1.3 Increasing research & development activities for drug development
3.2.1.4 Increased awareness about crohn's disease
3.2.2 Industry pitfalls & challenges
3.2.2.1 Complexity of disease management
3.2.2.2 Lack of curative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)
5.1 Key trends
5.2 Medication
5.2.1 Anti-inflammatory agents
5.2.2 Immunosuppressants
5.2.3 Antibiotics and antipyretics
5.2.4 Other medications
5.3 Nutritional therapy
5.4 Surgery
Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Parenteral
Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)
7.1 Key trends
7.2 Pediatric
7.3 Adult
7.4 Geriatric
Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals & clinics
8.3 Homecare settings
8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Amgen Inc.
10.3 AstraZeneca Plc
10.4 Biogen
10.5 Boehringer Ingelheim GmbH
10.6 Bristol Myerr Squibb
10.7 Eli Lilly and Company
10.8 Janssen Pharmaceuticals (Johnson & Johnson)
10.9 Merck & Co. Inc
10.10 Novartis AG
10.11 Pfizer, Inc.
10.12 Salix Pharmaceuticals, Inc.
10.13 Takeda Pharmaceutical Industries Limited
10.14 Viatris Inc. (Mylan N.V.)
